Q9993 HCPCS Level II code: Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
CMS terminated Q9993: its last date of service was Dec 31, 2018. It stays here for looking up older claims; newer services need a current code.
Official description
Q9993Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
Short description: Inj., triamcinolone ext rel
HCPCS · United States
Notes for Q9993
As CMS prints them, with any note Q9993 takes from the headings above it.
Note
- CMS processing note 0127: PUBLICATION 100.2, CHAPTER 15, 50.1.
Medicare details
The indicators CMS publishes with Q9993 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Cross-reference
- See J3304
- Added
- Jul 1, 2018
- Terminated after
- Dec 31, 2018
Where Q9993 sits
- 1Q codesTemporary codes
- 2Terminated Q9993Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code Q9993 still valid?
No. CMS terminated Q9993; its last date of service was Dec 31, 2018. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover Q9993?
CMS lists Q9993’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q9993
All Q codesQ9986Injection, hydroxyprogesterone caproate, (makena), 10 mgQ9987Pathogen(s) test for plateletsQ9988Platelets, pheresis, pathogen-reduced, each unitQ9989Ustekinumab, for intravenous injection, 1 mgQ9991Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mgQ9992Injection, buprenorphine extended-release (sublocade), greater than 100 mgQ9994In-line cartridge containing digestive enzyme(s) for enteral feeding, eachQ9995Injection, emicizumab-kxwh, 0.5 mgQ9996Injection, ustekinumab-ttwe (pyzchiva), subcutaneous, 1 mgQ9997Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mgQ9998Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mgQ9999Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg